Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

M3 Wake Research, Inc.

Neither a doctor nor a teaching hospital

Research payments

$11,400,571

240 payments

Through program year 2025, M3 Wake Research, Inc. is reported as receiving $11,400,571 in research payments, across 240 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $29,398 11
2024 Research $23,517 7
2023 Research $1,148,673 68
2022 Research $5,547,794 81
2021 Research $3,010,528 45
2020 Research $1,534,606 23
2019 Research $106,055 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $8,820,429 73 payments
  2. Janssen Pharmaceuticals, Inc $1,199,244 49 payments
  3. Emergent BioSolutions Inc. $748,236 12 payments
  4. Rhythm Pharmaceuticals, Inc. $190,743 42 payments
  5. Teva Pharmaceuticals USA, Inc. $159,388 12 payments
  6. Merck Sharp & Dohme Corporation $139,030 8 payments
  7. Medicines360 $112,674 13 payments
  8. Jazz Pharmaceuticals Inc. $23,431 28 payments
  9. Exeltis, USA Inc. $7,397 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants $7,427,570 66 payments
  2. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants $1,392,859 7 payments
  3. A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older $1,199,244 49 payments
  4. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $710,269 9 payments
  5. A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea $143,225 4 payments
  6. A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $138,875 6 payments
  7. A Phase 3 multicenter, open-label study of a Levonorgestrel 52 mg Intrauterine System for the treatment of heavy Menstrual Bleeding $112,674 13 payments
  8. Rm-493-022 $105,961 16 payments
  9. Rm-493-023 $40,427 9 payments
  10. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $29,467 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record